Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies

NCT00094159 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.

NCT NCT00094159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies
Lead sponsor
Sunesis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2004
Completion date
Not reported
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms